Recent advances in nanoformulations are reshaping the treatment landscape for helminthiasis by addressing critical challenges such as drug resistance, poor bioavailability, and off-target effects. This review examines current innovations in nanotechnology applied to anthelmintic therapy, with a particular focus on lipid- and polymer-based systems designed to enhance drug solubility, stability, and targeted delivery. A comprehensive literature search was performed to identify recent developments, highlight preclinical and translational studies, and evaluate the performance of solid lipid nanoparticles, nanoemulsions, and self-nanoemulsifying drug delivery systems. Relevant articles were retrieved from peer-reviewed journals indexed in PubMed, Scopus, and Web of Science, covering publications up to June 2025. The integration of nanotechnologies into helminthiasis treatment offers promising therapeutic advantages but faces important challenges related to industrial scalability, regulatory approval, and implementation in low-resource settings. Addressing these issues requires coordinated efforts between academia, industry, and public health stakeholders. The review outlines key considerations for technology transfer and commercialization, underscoring the importance of cost-effectiveness, patient acceptability, and cross-sector collaboration to ensure the successful translation of nanomedicine-based solutions for neglected tropical diseases.
No takes yet. Share an insight, caveat, or question.
Moraes et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: